Drug Trial Radar · NCT01215253
Ranolazine Implantable Cardioverter-Defibrillator Trial
Last checked: Nov 20, 2026Latest source record: Aug 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,012
Actual
Start
Sep 2011
Primary completion
Feb 28, 2017
Study completion Feb 28, 2017
Sponsor
- Lead sponsor
- University of RochesterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 6, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to see how effective a drug called ranolazine is in reducing the risk of ventricular arrhythmia and death in people with implantable cardioverter-defibrillators (ICDs). This drug will be used with standard medications that is routinely prescribed in enrolled patients.
Conditions
- Ischemic Cardiomyopathy
- Nonischemic Cardiomyopathy
- Heart Failure
Interventions
RanolazineDrug
At enrollment, patients will be randomized to ranolazine or placebo. In the active drug arm each patient will be started on a 500 mg twice a day dose for one week with subsequent increase to 1000 mg twice a day at beginning of second week.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients With Ventricular Tachycardia (VT) or Ventricular Fibrillation (VF) or DeathTime frame: 2 years of follow-up on average
Locations
90 sites in 2 countries. Site status is shown where the registry gives one.
University of Arizona
Tucson, Arizona
Arkansas Cardiology
Little Rock, Arkansas
Sequoia Hospital
East Palo Alto, California
Good Samaritan Hospital
Los Angeles, California
Huntington Memorial Hospital
Pasadena, California
Regional Cardiology Associates
Sacramento, California
Delta Heart and Medical Clinic
Stockton, California
University of Colorado Health - MHS
Colorado Springs, Colorado
Bridgeport Hospital
Bridgeport, Connecticut
Hartford Hospital
Hartford, Connecticut
Washington Electrophysiology/Cardiovascular Research Institute
Washington D.C., District of Columbia
Bay Area Cardiology Associates, P.A.
Brandon, Florida
University of Florida/Cardiovascular Medicine
Gainesville, Florida
University of Florida Health Science Center at Jacksonville
Jacksonville, Florida
Watson Clincia Center for Research Inc.
Lakeland, Florida
Florida Hospital
Orlando, Florida
Tallahassee Research Institute, Inc.
Tallahassee, Florida
Georgia Health Sciences University
Augusta, Georgia
Georgia Arrhythmia Consultants
Macon, Georgia
University of Chicago Hospital
Chicago, Illinois
Peakview Research Center
Fort Wayne, Indiana
LaPorte Hospital
Hobart, Indiana
University of Iowa
Iowa City, Iowa
Central Baptist Hospital
Lexington, Kentucky
Louisiana State University Health Sciences Center- New Orleans
New Orleans, Louisiana
University of Maryland Medical Center
Baltimore, Maryland
Johns Hopkins University
Baltimore, Maryland
MedStar Southern Maryland Hospital Center
Clinton, Maryland
Tufts-New England Medical Center
Boston, Massachusetts
Lahey Clinic
Burlington, Massachusetts
University of Massachusetts-Worchester
Worcester, Massachusetts
Henry Ford Hospital
Detroit, Michigan
William Beaumont Hospital - Royal Oak
Royal Oak, Michigan
Michigan Heart
Ypsilanti, Michigan
St. Luke's Hospital Association of Duluth
Duluth, Minnesota
University of Minnesota
Minneapolis, Minnesota
University of Mississippi Medical Center
Jackson, Mississippi
University of Missouri
Columbia, Missouri
Kansas City Heart Foundation
Kansas City, Missouri
Cooper University Hospital
Camden, New Jersey
Showing 40 of 90 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.